Paper4373589
Successful medical adrenalectomy with amino-glutethimide. Role of altered drug metabolism.
Santen RJ and 2 others. JAMA, 1974. Cited by 150 papers, by iCite.
Cite this record
ConductScience Library. Successful medical adrenalectomy with amino-glutethimide. Role of altered drug metabolism. Papers, record 4373589. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4373589
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Successful medical adrenalectomy with amino-glutethimide. Role of altered drug metabolism.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adrenal Cortex Hormones | Major topic |
| Adrenal Glands | Major topic |
| Aminoglutethimide | Major topic |
| Breast Neoplasms | Major topic |
| Dexamethasone | Major topic |
| Adrenalectomy | |
| Adrenocorticotropic Hormone | |
| Adult | |
| Aged | |
| Drug Interactions | |
| Female | |
| Half-Life | |
| Humans | |
| Hydrocortisone | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Secretory Rate |
Source PubMed
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 150 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 23625614 | Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. | Endocr Relat Cancer | 2013 | https://conductscience.org/library/papers/23625614 | PubMed |
| 16202169 | The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment. | Reprod Biol Endocrinol | 2005 | https://conductscience.org/library/papers/16202169 | PubMed |
| 8595171 | Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. | Br J Cancer | 1996 | https://conductscience.org/library/papers/8595171 | PubMed |
| 7749129 | Aromatase inhibitor development for treatment of breast cancer. | Breast Cancer Res Treat | 1995 | https://conductscience.org/library/papers/7749129 | PubMed |
| 7619329 | Antineoplastic agents. Drug interactions of clinical significance. | Drug Saf | 1995 | https://conductscience.org/library/papers/7619329 | PubMed |
| 7238450 | Factors affecting adrenocortical hormone function. | Environ Health Perspect | 1981 | https://conductscience.org/library/papers/7238450 | PubMed |
| 6690067 | Aminoglutethimide and warfarin. A new important drug interaction. | Cancer Chemother Pharmacol | 1984 | https://conductscience.org/library/papers/6690067 | PubMed |
| 6293627 | Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review. | Breast Cancer Res Treat | 1981 | https://conductscience.org/library/papers/6293627 | PubMed |
| 6221746 | Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6221746 | PubMed |
| 4042517 | Single-dose and steady-state pharmacokinetics of aminoglutethimide. | Clin Pharmacokinet | 1985 | https://conductscience.org/library/papers/4042517 | PubMed |
| 3912013 | Could aminoglutethimide replace adrenalectomy? | Breast Cancer Res Treat | 1985 | https://conductscience.org/library/papers/3912013 | PubMed |
| 3779118 | Aminoglutethimide-induced myelosuppression. | Breast Cancer Res Treat | 1986 | https://conductscience.org/library/papers/3779118 | PubMed |
| 3719899 | The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of warfarin in patients with breast cancer. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3719899 | PubMed |
| 3436111 | Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. | Clin Pharmacokinet | 1987 | https://conductscience.org/library/papers/3436111 | PubMed |
| 3358910 | The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients. | Br J Cancer | 1988 | https://conductscience.org/library/papers/3358910 | PubMed |
| 3048976 | Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. | Drugs | 1988 | https://conductscience.org/library/papers/3048976 | PubMed |
| 2963170 | On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. | Klin Wochenschr | 1987 | https://conductscience.org/library/papers/2963170 | PubMed |
| 2679845 | Treatment of breast cancer with aromatase inhibitors--current status and future prospects. | Br J Cancer | 1989 | https://conductscience.org/library/papers/2679845 | PubMed |
| 1847846 | Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. | Cancer Chemother Pharmacol | 1991 | https://conductscience.org/library/papers/1847846 | PubMed |
| 1505141 | Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. | Clin Pharmacokinet | 1992 | https://conductscience.org/library/papers/1505141 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4373589
GET https://conductscience.org/api/papers/v1/4373589/cited_by?page=2